Washington University Physicians at Barnes-Jewish Hospital deliver specialized care for people with amyloidosis. We are among the nation’s leading centers for amyloidosis treatment and research.
You receive care from doctors with expertise in treating amyloidosis. And we deliver exceptional treatment for every type of amyloidosis. These capabilities draw people from across the St. Louis region.
Amyloidosis Care: Why Choose Us?
Amyloidosis, a rare condition, occurs when an abnormal protein called amyloid accumulates in your organs. This protein buildup interferes with normal organ function and may lead to permanent organ damage. Amyloidosis currently has no cure, but treatment can slow the progression of the disease and preserve the health of your organs.
The Washington University Amyloid Center is a Center of Excellence, providing the highest level of care and improving treatments through research. We are one of the few centers in the country specializing in amyloidosis, offering a high level of care that’s not widely available. We provide an accurate diagnosis and advanced treatment options — even for rare forms of the disease.
You benefit from:
- Full range of care: Highly skilled doctors perform thorough testing, so you receive an accurate diagnosis. You have access to the latest treatments, which may include medications to prevent protein accumulation. Medications may also slow the rate at which your body produces proteins, lowering your risk for amyloidosis complications. We offer care that helps you feel better while lowering your risk of permanent organ damage. Read more about amyloidosis diagnosis and treatment.
- Access to clinical trials: Washington University Physicians are exploring new amyloidosis care techniques through clinical trials. You may be eligible to receive new medications that are only available in select centers around the world.
- National leadership: We host conferences for doctors and patients where we share the latest practices in amyloidosis care. We also publish our research findings in nationally recognized academic journals. Our efforts raise the level of amyloidosis care for people all over the country.
Team Approach to Amyloidosis Care
Amyloidosis often affects multiple organs, causing symptoms that require specialized care. Our highly skilled doctors work together to deliver the care you need. We are the only location in the St. Louis region using a team approach to treat amyloidosis. Our amyloidosis care team includes specialists in:
- Cancer and stem cell transplantation
- Digestive disease
- Heart care
- Kidney disease
- Liver disease
- Lung disorders (pulmonology)
- Nerve disorders
- Pathology (analyzing tissue to diagnose conditions)
Amyloidosis Clinical Trials
Our latest clinical trials include:
124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis
This is a single-center, exploratory, Phase 1 Positron Emission Tomography/X-ray Computed Tomography (PET/CT) imaging study to detect amyloidosis that will enroll patients with a confirmed diagnosis of systemic amyloidosis. The purpose of this exploratory trial is to assess the safety and efficacy of 124I-p5+14 Injection at a single-injection dose adequate for imaging amyloid deposits by using PET/CT imaging in subjects with confirmed systemic Immunoglobulin Light Chain-associated Amyloidosis (AL), Transthyretin-associated Amyloidosis (ATTR), Leukocyte Chemotactic Factor 2-associated Amyloidosis (ALect2) as well as other types.
A Global Study of NEOD001 in Patients With AL Amyloidosis
The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis (VITAL)
CyBorD +/- Daratumumab in AL (Light Chain) Amyloidosis
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis.
IXAZOMIB (MLN9708) or Standard Therapy for AL Amyloidosis
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Transthyretin-Associated Amyloidosis Survey (THAOS)
THAOS is a global survey open to all patients with transthyretin-associated amyloidoses (ATTR), including ATTR-PN (polyneuropathy), ATTR-CM (cardiomyopathy) and wild-type ATTR-CM. The goal is to better understand the disease by studying a large patient population. Survey data may be used to develop new treatment guidelines and recommendations and to inform and educate clinicians about the management of this disease.
ATTR Expanded Access Program (EAP) by Ionis
The purpose of this program is to provide expanded access to treatment for up to 100 Patients with Hereditary Transthyretin Amyloidosis (hTTR).
A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis). A study of a new subcutaneous formulation of a drug that lowers production of TTR RNA for patients with neurological manifestations of hereditary TTR amyloidosis.
Amyloidosis care is available at many Barnes-Jewish locations, including:
To make an appointment with a Washington University amyloidosis specialist at Barnes-Jewish Hospital, call 888.969.4806